Zydus Cadila gets USFDA nod to market generic cancer drug

Zydus Cadila gets USFDA nod to market generic cancer drug The company has received final approval from the United States Food and Drug Administration (USFDA) to market Erlotinib tablets in the strengths of 25 mg, 100 mg, and 150 mg, Zydus Cadila said in a statement.

No comments:

Post a Comment